TRMT2B: A Drug Target and Potential Biomarker (G79979)

Target Name: TRMT2B

NCBI ID: G79979

TRMT2B

TRMT2B: A Drug Target and Potential Biomarker

Transcript variants, also known as gene variants, are changes in the DNA sequence of a gene that occur at the level of transcription. These variants can result in the production of a different protein than the original protein, which may have different functions or properties. In the case of TRMT2B, also known as TRNA methyltransferase 2 homolog B, these changes in the DNA sequence have led to the production of a unique protein that has been shown to have a variety of functions, including involvement in the development and progression of cancer . As a result, TRMT2B has potential as a drug target and biomarker.

TRMT2B is a gene that encodes a protein involved in the transfer of methyl groups to specific locations on the DNA. The methylation of DNA is a critical process that plays a role in regulating gene expression and is also involved in the development and progression of cancer. Methylation of the promoter region of a gene can inhibit its expression, while methylation of the gene itself can result in its activation. TRMT2B is specifically involved in the transfer of methyl groups to the 5' end of the DNA, which is known as the coding region.

Studies have shown that TRMT2B is involved in the regulation of a wide range of cellular processes, including cell growth, apoptosis, and DNA replication. In addition, TRMT2B has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer.

One of the key features of TRMT2B is its ability to interact with other proteins. Studies have shown that TRMT2B forms a complex with the protein p53, which is a well-known tumor suppressor protein. This complex plays a role in the regulation of cellular processes such as cell growth, apoptosis, and DNA replication, and is thought to be involved in the development and progression of cancer.

Another study has shown that TRMT2B is involved in the regulation of the expression of the gene PDGF-尾, which is a protein that plays a role in the development and maintenance of tissues and organs. The results of this study suggest that TRMT2B may be involved in the regulation of the growth and development of tissues and organs, and may be a potential drug target.

In addition to its involvement in the regulation of cellular processes, TRMT2B has also been shown to have a role in the development and progression of cancer. Studies have shown that TRMT2B is involved in the regulation of the expression of genes involved in cell adhesion, migration , and invasion, which are all important processes involved in the development of cancer.

TRMT2B has also been shown to be involved in the regulation of the expression of genes involved in cell survival and angiogenesis, which are processes that are important in the development of cancer. In addition, TRMT2B has been shown to be involved in the regulation of the expression of genes involved in cell signaling pathways, which are important in the regulation of cellular processes and may be involved in the development and progression of cancer.

Given its involvement in a wide range of cellular processes and its involvement in the development and progression of cancer, TRMT2B has potential as a drug target and biomarker. Studies have shown that blocking TRMT2B activity with small molecules has the potential to inhibit the growth and survival of cancer cells. In addition, blocking TRMT2B activity with small molecules has the potential to enhance the effectiveness of chemotherapy by inhibiting the formation of blood-brain barrier, which is a barrier that allows cancer cells to access the and detoxify drugs that are necessary for treatment.

In conclusion, TRMT2B is a gene that encodes a protein involved in the transfer of methyl groups to specific locations on the DNA. These changes in the DNA sequence have led to the production of a unique protein that has been shown to have a variety of functions , including involvement in the development and progression of cancer. As a result, TRMT2B has potential as a drug target and biomarker. Studies have shown that blocking TRMT2B activity with small molecules has the potential to inhibit the growth and survival of cancer cells and enhance the effectiveness of chemotherapy by inhibiting the formation of blood-brain barrier. Further research is needed to fully understand the role of TRMT2B in the development and progression of cancer and its potential as a drug target and biomarker.

Protein Name: TRNA Methyltransferase 2 Homolog B

Functions: Mitochondrial S-adenosyl-L-methionine-dependent methyltransferase that catalyzes the formation of 5-methyl-uridine in tRNAs and 12S rRNA (PubMed:31948311, PubMed:34556860). Catalyzes the methylation of uridine at position 54 (m5U54) in all tRNAs (PubMed:31948311). Specifically methylates the uridine in position 429 of 12S rRNA (m5U429) (PubMed:31948311). Does not affect RNA stability or mitochondrial translation (PubMed:31948311)

The "TRMT2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRMT2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets